Digital therapy for managing paranoia in psychosis
Official title: SloMo2: A Process Evaluation, Effectiveness, and Cost-effectiveness Study of a Digitally Supported Therapy for Psychosis in Routine Care
Run by King's College London · NCT06568081 · Data updated 2026-11-12
This study is testing a new digital therapy to help people with schizophrenia and other psychotic disorders manage paranoia and racing thoughts in their daily lives.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 150 (estimated) |
| Sponsor | King's College London Academic / other |
| Locations | 1 site (London) |
| Status | Recruiting |
| Started | October 16, 2024 |
| Main results expected | September 2027 |
| Study ends | December 31, 2027 |
| Registry record updated | August 11, 2026 |
| Trial ID | NCT06568081 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals diagnosed with psychosis who are seeking therapy for paranoia and are in contact with secondary care mental health services.
✕Probably not a fit
Patients who are at acute risk of harm to themselves or others, or those with primary diagnoses of substance dependence or learning disabilities may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the implementation and effectiveness of SloMoR2, a digitally supported therapy designed to help individuals with schizophrenia and other psychotic disorders manage paranoia and fast thinking. The therapy, developed collaboratively with input from those with lived experience, therapists, and designers, aims to make cognitive behavioral therapy more accessible and practical in everyday life. Participants will receive therapy from both high and low intensity therapists, and outcomes will be assessed through questionnaires, software analytics, and interviews over a 24-month period. The study will take place across three NHS trusts in the UK.
Why it matters
Potential benefit: If successful, this therapy could significantly improve the quality of life for patients experiencing paranoia by providing them with effective coping strategies.
How similar studies have gone: Previous studies have shown that digitally supported therapies can be effective, suggesting a promising avenue for this approach, although SloMo itself is a novel intervention.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Meet criteria for ICD-10 psychosis diagnoses (F20-29, F30-39) * Seeking therapy for paranoia * In contact with secondary care mental health services * Capacity to provide informed consent to engage in therapy Exclusion Criteria: * Acute risk of harm to self or others * Unable to engage in therapy due to language barriers * Primary diagnosis of alcohol/substance dependence, learning disability, or organic brain injury or illness implicated in psychosis
Where it's running
-
South London and Maudsley NHS Foundation Trust
London, United Kingdom Recruiting
Study contacts
- Principal investigator: Amy Hardy — King's College London
- Study coordinator: Kathryn M Taylor
- Email: kathryn.taylor@kcl.ac.uk
- Phone: 07876876164
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Understanding early psychosis and its biological markers
This study is trying to find out more about early signs of psychotic disorders like schizophrenia and bipolar disorder by looking at brain scans and other health data from around 320 participants over a year.
-
Detecting immune inflammation and brain changes in schizophrenia
This study looks at how inflammation in the immune system might be linked to schizophrenia by comparing patients with the condition to healthy individuals over three months.
-
Metabolic care for patients with severe mental illness
This study is testing a special clinic for people with severe mental illness to see if it helps them manage weight and heart health better than regular care.
-
Education on sexual dysfunction for patients with schizophrenia and diabetes
This study tests whether providing education about sexual dysfunction can help adults with schizophrenia and diabetes feel better about their sexual health while they are on antipsychotic medication.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.